Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.46 |
| ▸ | PGR | P06401 | 3/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | HTR5A | P47898 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16158285 | 0.85 | AR (0.43) | ARPGRNR3C2HTR5AKDM4E | |
| SCHEMBL19155889 | 0.81 | HTR5A (0.42) | HTR5AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL10840954 | 0.80 | AR (0.48) | ARPGRNR3C2HTR5A | |
| SCHEMBL5328438 | 0.80 | AR (0.47) | ARPGRNR3C2 | |
| SCHEMBL10841146 | 0.80 | AR (0.47) | ARPGRNR3C2HTR5AADRA2A | |
| SCHEMBL10841369 | 0.77 | AR (0.46) | ARPGRNR3C2 | |
| SCHEMBL6986056 | 0.77 | PDE3B (0.46) | ARHTR5AALDH1A1ADRA2A | |
| SCHEMBL10841318 | 0.77 | AR (0.44) | ARPGRNR3C2 | |
| SCHEMBL10840081 | 0.76 | MAPT (0.52) | ARPGRNR3C2MAPTADRA2A | |
| SCHEMBL10840611 | 0.76 | AR (0.47) | ARPGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359285-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-09 | — | — | US | disclosed |
| US-8865918-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| US-8519158-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-11-01 | — | — | US | disclosed |
| WO-2005090282-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-29 | — | — | WO | disclosed |
| EP-0198264-A2 | Carbamoyl imidazoles | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | AR, SHBG, NR5A1 | AR 1/4885PGR 30/4885NR3C2 18/4885 |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | AR, SHBG, NR5A1 | AR 1/4885PGR 30/4885NR3C2 18/4885 |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | AR, SHBG, NR5A1 | AR 1/4885PGR 30/4885NR3C2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.